Stoke Therapeutics, Inc.
No enriched coverage for $STOK in the last 7 days.
The U.S. Space Force, via Space Systems Command, modified NSSL Phase 3 Lane 1 launch-service contracts for seven companies, raising the contract ceiling from $5.6B to $17B. Awardees include Blue Origin, Impulse Space, Relativity Federal, Rocket Lab USA, SpaceX, Stoke Space Technologies, and ULA. No funds were obligated at award.
The U.S. Space Force expanded the NSSL Phase 3 Lane 1 vendor pool to seven companies, adding Impulse Space and Relativity Federal on July 7. Initial providers were SpaceX, Blue Origin, and ULA in June 2024, with Rocket Lab and Stoke Space added in March 2025. Lane 1 supports lower-risk national security launches; SpaceX has most awarded task orders.
TechCrunch reports Kevin Weil, a former OpenAI and Meta executive, joined the board of Seattle startup Stoke Space. Stoke says Weil will help with scaling and fundraising after the company raised $1.34 billion, including a $510 million Series D in 2025, to develop reusable rocket Nova aimed to fly this year.
Recent STOK coverage spans financial news and insider activity.
In the last 30 days, STOK insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($208K). The most active reporter was Ticho Barry, CHIEF MEDICAL OFFICER, with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The ceiling increase expands the potential contract value available to Stoke under Lane 1.
Lane 1 eligibility can improve visibility for future NSSL task orders, but the article does not announce a new Stoke-specific award or terms.
Board addition of a high-profile AI and defense-adjacent executive may improve fundraising and strategic partnerships, but it is not a near-term operational milestone.
Insider selling under a pre-arranged 10b5-1 plan is typically low-signal, but it can modestly affect near-term sentiment.
Despite the headline, the provided text is dominated by AI/robotics hype and subscription marketing, with no specific Q1 figures or concrete STOK guidance/details included.
alphai scores every news story that mentions STOK with an AI model for sentiment and relevance, and aggregates insider trades from Stoke Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The U.S. Space Force, via Space Systems Command, modified NSSL Phase 3 Lane 1 launch-service contracts for seven companies, raising the contract ceiling from $5.6B to $17B. Awardees include Blue Origin, Impulse Space, Relativity Federal, Rocket Lab USA, SpaceX, Stoke Space Technologies, and ULA. No funds were obligated at award.
4 min readThe U.S. Space Force expanded the NSSL Phase 3 Lane 1 vendor pool to seven companies, adding Impulse Space and Relativity Federal on July 7. Initial providers were SpaceX, Blue Origin, and ULA in June 2024, with Rocket Lab and Stoke Space added in March 2025. Lane 1 supports lower-risk national security launches; SpaceX has most awarded task orders.
7 min readTechCrunch reports Kevin Weil, a former OpenAI and Meta executive, joined the board of Seattle startup Stoke Space. Stoke says Weil will help with scaling and fundraising after the company raised $1.34 billion, including a $510 million Series D in 2025, to develop reusable rocket Nova aimed to fly this year.
6 min readTicho Barry (CHIEF MEDICAL OFFICER) sold 1,795 shares of Stoke Therapeutics, Inc. (STOK) at $30.58 on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readThe article is largely promotional and does not provide verifiable details of Stoke Therapeutics’ Q1 results. It instead discusses broad AI/robotics claims attributed to figures such as Andy Jassy and Elon Musk, and promotes a newsletter subscription. No specific STOK financial figures, guidance, or investor implications are stated.
4 min readStoke Therapeutics (Nasdaq: STOK) announced it will host a webcast and conference call on Thursday, May 7, 2026, at 4:30 p.m. ET, to provide first quarter 2026 business and financial updates. The event will be accessible via their investor website, with registration details provided for analysts participating in the Q&A. Stoke Therapeutics is a biotechnology company focused on RNA medicine with its lead investigational medicine, zorevunersen, in development for Dravet syndrome.
2 min readStoke Therapeutics announced the appointment of Dr. Clare Kahn as an independent Class I director to its board, expanding it to ten members. Dr. Kahn brings over 30 years of experience in drug development and regulatory affairs, which Stoke plans to leverage as it advances its Phase 3 trials for zorevunersen, an RNA-based therapy for Dravet syndrome. This strategic move aims to strengthen the company's governance and R&D oversight during a critical phase for its lead therapeutic candidate.
4 min readStoke Therapeutics (NASDAQ:STOK) insider Jason Hoitt sold 1,931 shares of the company's stock on March 18th for a total of $60,517.54, reducing his stake by 15.82%. This follows a previous sale of 1,781 shares on March 17th. The stock recently traded up 7.0%, reaching $33.19, amidst a mix of positive analyst sentiment regarding its pipeline and negative news concerning missed quarterly earnings and potential dilution from inducement stock options.
3 min readStoke Therapeutics (NASDAQ:STOK) CFO Thomas Leggett sold shares totaling approximately $72,489.96 on March 17th and $74,651.88 on March 18th, reducing his stake by nearly 15%. This comes as STOK rallied 7.0% due to positive analyst ratings, despite the company missing quarterly earnings and revenue expectations, and the potential for future dilution from inducement stock options. The company, focused on genetic medicines for neurological disorders, maintains a "Moderate Buy" consensus rating from analysts with an average price target of $39.83.
3 min readStoke Therapeutics General Counsel Jonathan Allan sold 4,267 shares of STOK stock for $140,853.67 on March 17th, and an additional 4,628 shares on March 18th for $145,041.52, reducing his stake by 11.31%. This insider selling comes amidst mixed signals, with analysts generally bullish with a "Moderate Buy" consensus and an average price target of $39.83, but the company recently missed quarterly EPS and revenue expectations. Stoke Therapeutics, a clinical-stage biopharmaceutical company, focuses on genetic medicines for rare neuromuscular and neurological disorders using its TANGO™ platform, with its lead program STK-001 targeting Dravet syndrome.
3 min read
